UPDATE - SPR® Therapeutics Announces Publication of Study Providing Evidence of the Impact of SPRINT® PNS Treatment in Relieving Postoperative Knee Pain
14 mai 2024 18h33 HE
|
SPR Therapeutics, Inc.
Publication of study provides evidence of the impact of SPRINT PNS in relieving post-operative knee pain after total knee arthroplasty (TKA).
SPR® Therapeutics Announces Publication of Study Providing Evidence of the Impact of SPRINT® PNS Treatment in Relieving Postoperative Knee Pain
13 mai 2024 14h16 HE
|
SPR Therapeutics, Inc.
Publication of study provides evidence of the impact of SPRINT PNS in relieving post-operative knee pain after total knee arthroplasty (TKA).
SPR® Therapeutics Announces $85 Million in Additional Funding to Advance Rapid Commercial Expansion of the SPRINT® PNS System
01 févr. 2024 09h00 HE
|
SPR Therapeutics, Inc.
SPR Therapeutics Announces $85 Million in Additional Funding to Advance Commercial Expansion of SPRINT PNS System.
SPR® Therapeutics Announces Extensive Set of Abstracts to be Shared at North American Neuromodulation Society (NANS) Annual Meeting 2024
16 janv. 2024 09h00 HE
|
SPR Therapeutics, Inc.
SPR Therapeutics and the SPRINT PNS System will be featured prominently at the North American Neuromodulation Society Annual Meeting with 11 abstracts.
New SPR Therapeutics Data Presented at ASRA Pain Medicine Meeting 2023
13 nov. 2023 09h05 HE
|
SPR Therapeutics, Inc.
Three SPR Posters Accepted Including a President’s Choice Award for New Data from Randomized Controlled Trial on Total Knee Replacement Postoperative Pain
Aptean stärkt sein strategisches Netzwerk in der DACH-Region
18 juil. 2022 09h30 HE
|
Aptean Inc.
ALPHARETTA, Ga., July 18, 2022 (GLOBE NEWSWIRE) -- Aptean, ein globaler Anbieter von Softwarelösungen für geschäftskritische Prozesse, gab heute die Erweiterung seines Partnernetzwerks auf dem...
Aptean Strengthens Its Strategic Network in the DACH Region
18 juil. 2022 09h30 HE
|
Aptean Inc.
ALPHARETTA, Ga., July 18, 2022 (GLOBE NEWSWIRE) -- Today, Aptean, a global provider of mission-critical enterprise software solutions, announced the expansion of its partner network in the Swiss...
Ondine Receives Innovation Award of Excellence at World-leading Infection Conference, ICPIC 2021 for Photodisinfection Efficacy Results against COVID-19 Virus Variants including Delta
22 sept. 2021 05h00 HE
|
Ondine Biomedical Inc.
Vancouver, Canada, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Ondine’s nasal photodisinfection technology has been shown to eliminate the RNA signature of SARS-CoV-2, including the dominant Delta variant,...
Preventing COVID-19 with Photodisinfection – New Results Presented at European Society of Photobiology
18 sept. 2021 01h27 HE
|
Ondine Biomedical Inc.
Vancouver, Canada, Sept. 18, 2021 (GLOBE NEWSWIRE) -- Nasal decolonization is recommended by the WHO and CDC to reduce hospital acquired infections (HAIs), [1] which have been exacerbated by COVID....
Ondine Biomedical to present SARS-CoV-2 results at the 19th Congress of the European Society of Photobiology
03 août 2021 06h00 HE
|
Ondine Biomedical Inc.
Vancouver, Canada, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Ondine's technology platform is capable of painlessly and rapidly destroying a broad spectrum of bacteria, fungi, and viruses — including...